EV / EBITDA společnosti Horizon Discovery plc
Jaká je hodnota metriky EV / EBITDA společnosti Horizon Discovery plc?
Hodnota metriky EV / EBITDA společnosti Horizon Discovery Group plc je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na LSE ve srovnání se společností Horizon Discovery plc
Čemu se věnuje společnost Horizon Discovery plc?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Firmy s metrikou ev / ebitda podobnou společnosti Horizon Discovery plc
- Hodnota metriky EV / EBITDA společnosti Genufood Enzymes je N/A
- Hodnota metriky EV / EBITDA společnosti Prairie Mining je N/A
- Hodnota metriky EV / EBITDA společnosti KemPharm je N/A
- Hodnota metriky EV / EBITDA společnosti Luxey International () je N/A
- Hodnota metriky EV / EBITDA společnosti Graphene Manufacturing je N/A
- Hodnota metriky EV / EBITDA společnosti Cassius Mining je N/A
- Hodnota metriky EV / EBITDA společnosti Horizon Discovery plc je N/A
- Hodnota metriky EV / EBITDA společnosti Seeing Machines je N/A
- Hodnota metriky EV / EBITDA společnosti Coppermoly je N/A
- Hodnota metriky EV / EBITDA společnosti Trillium Therapeutics je N/A
- Hodnota metriky EV / EBITDA společnosti Tianjin Development je N/A
- Hodnota metriky EV / EBITDA společnosti Crown International je N/A
- Hodnota metriky EV / EBITDA společnosti Zhihu je N/A